Triple therapie orale dans le diabete de type 2.

Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2/drug therapy; Drug Therapy, Combination; Humans; Hypoglycemic Agents/therapeutic use; Metformin/administration & dosage; Sulfonylurea Compounds/administration & dosage; Thiazolidinediones/administration & dosage; Treatment Outcome

Abstract :

[en] Type 2 diabetes has a complex pathophysiology, combining a defect of insulin secretion by the pancreas, an increased glucose production by the liver and a reduced insulin-mediated glucose uptake by the skeletal muscle. Each of these abnormalities can be partially reversed by a specific drug, an agent promoting insulin secretion (sulphonylurea or glinide), metformin and a thiazolidinedione (glitazone), respectively. Therefore, a triple oral therapy, targeting simultaneously the three main metabolic abnormalities of type 2 diabetes, deserves special attention. Recent clinical trials have shown both the efficacy and safety of this triple oral therapy. However, its precise place remains to be better specified in the overall management of type 2 diabetes.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Triple therapie orale dans le diabete de type 2.

Alternative titles :

[en] Triple oral therapy in type 2 diabetes

Publication date :

2005

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

Pages :

1942, 1944-6, 1948

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.revmed.ch

Available on ORBi :

since 05 May 2009

Statistics

Number of views

65 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003;38:335-41.
DeFronzo RA. The triumvirate: B-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-87.
Scheen AJ, Lefèbvre PJ. Oral antidiabetic drugs: A guide to selection. Drugs 1998;55:225-36.
Scheen AJ. Treatment of type 2 diabetes. Acta Clin Belg 2003;8:318-24.
Riddle MC. Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005;34:77-98.
Krentz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.
Davidson MB. Triple therapy. Definitions, application, and treating to target. Diabetes Care 2004;27:1834-5.
Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preservation of beta-cell function in type 2 diabetes mellitus. Drugs 2005;65:1-13.
Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of Type 2 diabetes. Diabetologia 2003;46(Suppl. 1):M44-M50.
Ahmann AJ, Riddle MC. What to do when two oral agents fail to control type 2 diabetes - A matter of opinion or a matter of fact? Am J Med 2004;116:276-8.
Yale JF, Valiquett TR, Ghazzi MN, et al. for the Troglitazone Triple-Therapy Study Group. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. Ann Intern Med 2001;134:737-45.
Jones N, Jones T Menci L, et al. Rosiglitazone in combination with glibendamide plus metformin is effective and well tolerated in type I diabetes patients (abstract). Diabetologia 2001;44(Suppl. 1):A904.
Kiayias JA, Vlachou ED, Theodosopoulou E, et al. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care 2002;25:1251-2.
Byrne J, Garg S, Vaidya A, et al. Efficacy of triple combination oral therapy using rosiglitazone, metformin, and sulphonylurea in lowering HbA1c. Pract Diab Int 2003;20:58-60.
Dailey GE, Noor MA, Park J-S, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial. Am J Med 2004;116:223-9.
Roy R, Navar M, Palomeno G, Davidson MB. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: A systematic evaluation of triple oral therapy in a minority population. Diabetes Care 2004;27:1741-2.
Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 2002;8:271-5.
Schwartz S, Sievers R, Strange P, et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: Efficacy, safety, and cost-analysis. Diabetes Care 2003;26:2238-43.
Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: A prospective, randomized trial. Am J Med 2004;116:230-5.
Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes (T2DM): Benefits of insulin glargine (GLAR) over rosiglitazone (RSG) added to combination therapy of sulfonylurea plus metformin (SU+ MET) in insulin-naive patients (abstract). Diabetes 2004;53(Suppl. 2):A145.
Braunstein S. New developments in type 2 diabetes mellitus: Combination therapy with a thiazolidinedione. Clin Ther 2003;25:1895-917.
Consoli A, Gomis R, Halimi S, et al. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: An evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004;30:509-16.
Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72.
Tiikkainen M, Häkkinen A-M, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-76.
Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80.